- Home
- PGNY vs IMCR Comparison
PGNY vs IMCR Comparison
Compare PGNY & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGNY
- IMCR
- Stock Information
- Founded
- PGNY 2008
- IMCR 2008
- Country
- PGNY United States
- IMCR United Kingdom
- Employees
- PGNY N/A
- IMCR N/A
- Industry
- PGNY Misc Health and Biotechnology Services
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PGNY Health Care
- IMCR Health Care
- Exchange
- PGNY Nasdaq
- IMCR Nasdaq
- Market Cap
- PGNY 1.8B
- IMCR 1.6B
- IPO Year
- PGNY 2019
- IMCR 2021
- Fundamental
- Price
- PGNY $23.21
- IMCR $35.00
- Analyst Decision
- PGNY Buy
- IMCR Buy
- Analyst Count
- PGNY 8
- IMCR 10
- Target Price
- PGNY $22.86
- IMCR $58.13
- AVG Volume (30 Days)
- PGNY 1.2M
- IMCR 389.0K
- Earning Date
- PGNY 08-07-2025
- IMCR 08-07-2025
- Dividend Yield
- PGNY N/A
- IMCR N/A
- EPS Growth
- PGNY N/A
- IMCR N/A
- EPS
- PGNY 0.57
- IMCR N/A
- Revenue
- PGNY $1,213,181,000.00
- IMCR $333,581,000.00
- Revenue This Year
- PGNY $7.09
- IMCR $26.82
- Revenue Next Year
- PGNY $11.68
- IMCR $8.15
- P/E Ratio
- PGNY $40.97
- IMCR N/A
- Revenue Growth
- PGNY 9.46
- IMCR 25.75
- 52 Week Low
- PGNY $13.39
- IMCR $23.15
- 52 Week High
- PGNY $30.42
- IMCR $41.54
- Technical
- Relative Strength Index (RSI)
- PGNY 58.94
- IMCR 59.78
- Support Level
- PGNY $21.09
- IMCR $32.20
- Resistance Level
- PGNY $24.66
- IMCR $35.75
- Average True Range (ATR)
- PGNY 0.88
- IMCR 1.31
- MACD
- PGNY 0.26
- IMCR 0.28
- Stochastic Oscillator
- PGNY 66.28
- IMCR 84.94
About PGNY Progyny Inc.
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.